secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2023-03-08T23:59:59+00:00
Accession:  0001213900-23-018553
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q4 revenue $19.7M (-3% YoY); guides FY23 revenue growth at least 10%
-------------------------------------------------------------------------------

- Q4 revenue $19.7M (-3% YoY), gross profit $12.5M (+1%), GAAP net loss $0.3M ($0.02 loss per share).
- Non-GAAP net income $4.4M ($0.25 per diluted share).
- FY22 revenue up 2%, generated $10.7M cash from ops, repurchased 1.2M shares at avg $16.49.
- Exited 2022 with six RWD-AI deals; pipeline of several dozen.
- FY23 guidance: revenue growth at least 10% YoY, gross margin 58-62%; Q1 revenue $11.5-13M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000121390023018553/0001213900-23-018553-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000121390023018553/ea174846-8k_optimizerx.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-018553

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer